Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;31(4):336-41.
doi: 10.4103/0970-2113.142101.

Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai

Zarir F Udwadia  1 , Gautam Moharil  1
Affiliations

Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai

Zarir F Udwadia et al. Lung India. 2014 Oct.

Abstract

Background: There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this study is to provide characteristics and treatment outcomes of a prospective cohort of MDR-TB patients managed at a private tertiary referral institute.

Materials and methods: A prospective analysis of a cohort of MDR-TB patients treated in a tertiary private hospital, with the back-up of a Level 2 mycobacterial laboratory, which has recently received recognition by the Revised National Tuberculosis Control Program (RNTCP) for second-line drug susceptibility (DST). All patients received an individualized MDR regimen on an ambulatory basis.

Results: Our 68% success rates are respectable and show that given the right laboratory backing, MDR-TB can be managed successfully in selected private practice settings.

Keywords: India; individualized regimens; multidrug-resistant tuberculosis; private practitioners; private sector.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Drug-specific resistance pattern
Figure 2
Figure 2
Number of drugs to which the patients were resistant: Patients had a mean resistance to 4.3 drugs
See this image and copyright information in PMC

References

    1. Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: Retrospective-prospective cohort study from 2004 to 2007. Euro Surveill. 2013;18:20601. - PubMed
    1. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153–61. - PubMed
    1. World Health Organization Report 2013 (Global Tuberculosis Report, 2013) [Last accessed on 2014 May 27]. Available from: http://www.who.int/tb/publications/global_report/en .
    1. D’souza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, et al. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health. 2009;9:211. - PMC - PubMed
    1. Bemer P, Palicova F, Rüsch-Gerdes S, Drugeon HB, Pfyffer GE. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2002;40:150–4. - PMC - PubMed